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Indicators of VL transmission 
Summary 
Risk of recrudescence of VL after scaling down control efforts can be monitored by means of 
population-based surveys measuring seroprevalence or antigenaemia. This study highlights the 











Background: Control of visceral leishmaniasis (VL) on the Indian subcontinent has been highly 
successful. Control efforts such as indoor residual spraying and active case detection will be scaled 
down or even halted over the coming years. We explored how after scale-down, potential 
recurrence of VL cases may be predicted based on population-based surveys of antibody or 
antigenaemia prevalence.  
Methods: Using a stochastic age-structured transmission model of VL, we predicted trends in case 
incidence and biomarker prevalence over time after scaling down control efforts when the target of 
three successive years without VL cases has been achieved. Next, we correlated biomarker 
prevalence with the occurrence of new VL cases within 10 years of scale-down. 
Results: Occurrence of at least one new VL case in a population of 10,000 was highly correlated with 
the seroprevalence and antigenaemia prevalence at the moment of scale-down, or one or two years 
afterwards. Receiver operating characteristic curves indicated that biomarker prevalence in adults 
provided the most predictive information, and seroprevalence was a more informative predictor of 
new VL cases than antigenaemia prevalence. Thresholds for biomarker prevalence to predict 
occurrence of new VL cases with high certainty were robust to variation in pre-control endemicity. 
Discussion: The risk of recrudescence of VL after scaling down control efforts can be monitored and 
mitigated by means of population-based surveys. Our findings highlight that rapid point-of-care 
diagnostic tools to assess (preferably) seroprevalence or (otherwise) antigenaemia in the general 
population could be a key ingredient of sustainable VL control. 
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Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne infection that can lead to long-
lasting fevers and death if left untreated, although most infected individuals will remain 
asymptomatic [1,2]. In the Indian sub-continent, where the disease is considered to only occur in 
humans, about 5-10% of those who are treated for VL develop post-kala-azar dermal leishmaniasis 
(PKDL), an infectious but self-limiting skin condition [3]. In 2005, India, Nepal, and Bangladesh 
committed to controlling VL by signing a trilateral Memorandum of Understanding. The associated 
continent-wide control measures led to a steep decrease of reported VL incidence from 32,803 in 
2005 to 3,128 in 2019, representing a 90% drop [4]. Control measures consist of vector control 
through indoor-residual spraying (IRS) of insecticide and active case detection (ACD) followed by 
prompt treatment, which is provided for free [5]. The goal is to achieve elimination of VL as a public 
health problem on the Indian subcontinent, which is defined as <1 new or recurring VL case per 
10,000 individuals per year at district or sub-district level [6]. To validate achievement of the target, 
the World Health Organization (WHO) requires that the VL incidence in a region is below the target 
for three years in a row in combination with extensive testing. After validation, control measures can 
be scaled down [7]. 
 
Many Indian sub-districts have entered or will be entering this validation phase in the coming years. 
The prospect of scaling down or even halting control measures, without complete interruption of 
transmission, poses a risk of recrudescence of infection. This highlights the need for continued 
monitoring of ongoing infection. In this study we assess the predictive power of population surveys 
employing serological tests (e.g. the direct agglutination test or DAT for antileishmanial antibody 
detection) or antigen tests to predict the occurrence of new VL cases (reported or unreported) after 
scaling down control efforts. To this end we developed a new stochastic age-structured VL 
transmission model, based on an established deterministic VL transmission model [8–11]. 
 
Methods 
Model structure and quantification 
We use an established age-structured deterministic VL transmission model that describes the 
transmission of VL between humans and sand flies on the Indian subcontinent [8–11]. To realistically 
simulate the probability of interrupting VL transmission, we developed a new stochastic version of 
the model, considering a finite and discrete number of homogeneously mixing human individuals 
while keeping the sand fly part of the model deterministic. In the model, most infected individuals 
remain asymptomatic and recover without ever having symptoms; a small fraction (~1.5%) of 
individuals become symptomatic and will require treatment or die otherwise; a small fraction (~3%) 
of symptomatic cases is assumed to recover spontaneously. Transmission is driven by exposure to 
sand flies, where sand fly abundance is assumed to peak from July to September of each year [12]. 
Sand flies can pick up infection from symptomatic cases, as well as individuals with PKDL, a self-
limiting but long-lasting skin condition that occurs in a fraction of individuals treated for VL (2.5% in 
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do (model E1) or do not (model E0) contribute to transmission. The model incorporates IRS coverage 
through a proportional reduction in the sand fly population density, and ACD through a decrease in 
the average detection delay of symptomatic cases (pre-control delay of 60 days [9,13]). In the 
model, we assume that seropositivity based on the DAT is associated with the late asymptomatic 
stage of infection (i.e. after individuals have been infected for a while), as well as the symptomatic 
stages and the early recovered stage (after which DAT positivity, and thus the humoral immune 
response, is lost again) [8]. DAT positivity was defined at the 1:800 titre cut-off, instead of the 
standard of 1:1600, which increases test sensitivity but decreases specificity. In contrast, we assume 
that antigenaemia (i.e. the persistence of antigen in circulating blood) is only associated with the late 
asymptomatic stage and the symptomatic stages when parasite loads are presumably highest. The 
model assumes that no infection can be introduced from outside the population. 
 
Model parameters were previously calibrated based on age-structured data from approximately 
21,000 individuals included in the KalaNet bednet trial in India and Nepal [8,14,15]. Age patterns in 
DAT and PCR positivity (where PCR positivity included the stage of infection that we consider antigen 
positive here, along with the early stage of asymptomatic infection) were reproduced assuming that 
exposure to bites of sand flies increase linearly from zero at birth to a maximum value at age 20, and 
plateaus thereafter (crudely reflecting change of body surface area with age). The impact of IRS was 
previously estimated using a geographical cross-validation on decreasing case incidence in Bihar 
(~6,000 VL cases in 8 districts over a period of 18 months) [9,13]. A schematic representation of the 
model structure and an overview of model parameter values are presented in the Supplementary 
Information (Figure S1 and Table S1, respectively). 
 
The model was coded in R (version 4.0.2), using the pomp package (version 3.1.1.7); the model code 
is publicly accessible at https://gitlab.com/erasmusmc-public-health/vl-serosurveys. We provided 
the Policy-Relevant Items for Reporting Models in Epidemiology of Neglected Tropical Diseases 
(PRIME-NTD) Summary in Table S2, which was previously established to set a standard and increase 
consistency among modelling studies that aim to inform policy [16]. 
 
Simulation scenarios 
With each version of the stochastic transmission model (E0 and E1), we performed 10,000 repeated 
simulations for a stable population of 10,000 people. Transmission conditions (i.e. the sand fly to 
human ratio) were allowed to vary randomly between simulations such that the pre-control VL 
incidence ranged from 2 to 15 reported VL cases per 10,000 capita per year, as expected under the 
deterministic version of the model. During the pre-control phase we assumed that only passive case 
detection was in place, leading to an average duration between the start of symptoms and the start 
of treatment of 60 days [13]. To start a stochastic simulation, we extracted the expected pre-control 
equilibrium state of the human and fly population (i.e. distribution over model compartments) from 
a deterministic simulation based on the same transmission conditions. This population state was 
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distribution. Based on this seeding, we ran the stochastic model, implementing control measures as 
recommended by WHO until zero VL cases were observed (i.e. only reported cases) for three 
consecutive calendar years (i.e. a period starting on January 1st and ending in December 31st three 
years later). Control efforts were assumed to start with a 5-year attack phase in which we assumed 
that IRS covers 67% of the population and that ACD reduces the time to treatment to an average of 
45 days. Subsequently, during the so-called consolidation phase, IRS coverage was reduced to 45%, 
but ACD efforts are further increased leading to an average duration to treatment of 30 days. 
Achievement of the target (three consecutive years with zero reported VL cases, with rigorous ACD) 
was assessed from completion of the attack phase onwards, meaning that at least eight years of 
control had been performed before any control programme was allowed to scale down. If a 
simulation did not achieve the target of three consecutive years with zero reported VL cases within 
20 years of control efforts (which happens more often if asymptomatic infections do not contribute 
to transmission [9], i.e. in model E0), it was discarded and excluded from further analysis. For those 
simulations in which the target was met, control efforts were scaled down to the pre-control 
situation (no IRS and no ACD such that the average detection delay returned to 60 days) and the 
simulation was continued for another 10 years to see if any new VL cases (reported or unreported) 
would occur. 
 
To see if the occurrence of at least one new VL case could be predicted based on prevalence of 
biomarkers in the population, we saved model-predicted trends in age-specific prevalence of DAT 
and antigenaemia prevalence. Receiver operating characteristic (ROC) curves as well as positive 
(PPV) and negative predictive values (NPV) of thresholds for biomarker prevalence were calculated 
for three different time points: at the moment of scaling down control efforts, and one and two 
years after the scale-down. For the last two time points, we excluded simulations in which one or 
more VL cases were already detected before the time of the survey, assuming that this observation 
alone would already lead to policy action. For each survey, we assumed that a random subset of 500 
individuals in the population is tested, simulating 100 random surveys for each time point in each 
simulation. Simulated surveys sampled either only pre-school age children (ages 0-4), school-age 
children (ages 5-14), or adults (ages ≥15). Threshold values were expressed in terms of the number 
of biomarker-positive individuals among this sample of 500 at or above which we expect recurrence 
of at least one VL case in the 10 years following scaling down of control efforts. 
  
Results 
Out of the 10,000 repeated stochastic simulations that were performed with each model variant, in 
8,011 (model E1) and 4,705 simulations (model E0) the target of three consecutive years of zero 
reported VL cases was achieved within 20 years of control and control could be scaled down to 
passive case detection only. The probability of at least one new VL case occurring within 10 years 
after scaling down control was higher in model E0 (2,936 / 4,705 = 62.4%) than in model E1 (3,028 / 
8,011 = 37.8%). If one or more new VL cases occurred, the first case typically occurred within the 
first year after scaling down (96.5% of simulations in model E1 and 69.3% in model E0), but with a 
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the first detected case was slightly later, although still typically within one year after scaling down 
(93.7% of simulations in model E1 and 60.3% in model E0). 
 
If a new VL case occurred after scaling down control, model E1 predicted that DAT prevalences were 
above 0% for at least two years after scale down (100% of simulations, Table S3) and fluctuated and 
rose over time (Figure 1). DAT prevalences reached higher values in adults (age 15+) than in pre-
school (age 0-4) and school-aged children (age 5-14), reflecting the assumed age patterns in 
exposure to sand fly bites. If no new VL cases occurred and DAT prevalences were above 0% at the 
moment of scale-down (45% of the simulations), the DAT prevalence quickly declined to values close 
to zero within one to two years. Trends in antigenaemia prevalence followed a similar pattern, 
although with overall lower prevalences compared to DAT (Figure S3), reflecting that the duration of 
antigen-positivity is shorter than that of seropositivity. If no new VL case occurred after scale-down, 
antigenaemia prevalence was rarely above 0% at the moment of scale-down (13% of simulations); if 
a new VL case did occur, antigenaemia prevalence was almost always above 0% (99% of simulations; 
Table S4). Predicted trends in biomarker prevalence and the differences in trends between 
simulation outcomes (absence vs. occurrence of new VL cases) were qualitatively similar between 
model E1 (Figure 1 and Figure S3) and model E0 (Figures S4 and S5). DAT prevalences in children < 15 
were slightly lower at the turn of each year due to the fact that at that moment in the simulation, for 
efficiency, all individuals were assumed to simultaneously age by one year. This modelling artefact is 
not visible for antigenaemia prevalence due to the higher level of stochastic noise associated with 
overall lower prevalences. 
  
Sensitivity and specificity of different thresholds for biomarker prevalence as predicted by model E1 
for samples of 500 individuals are illustrated as ROC curves in Figure 2. Because biomarker 
prevalences were generally higher in adults (age 15+) and thus suffered less from stochastic noise, 
sensitivity and specificity of thresholds were highest when applied to prevalences in that particular 
age group. This pattern was qualitative similar for model E0 (Figure S6), although sensitivity and 
specificity were lower overall than in model E1 and the difference in ROC curves based on biomarker 
prevalences in adults (age 15+) and school-aged children (age 5-14) was somewhat larger. Still, the 
two model variants agreed that a threshold of 1 to 3 biomarker-positive cases in a sample of 500 
was optimal to achieve both high sensitivity and specificity, and that DAT prevalence was a more 
informative predictor of recurrence of VL cases than antigenaemia prevalence. Furthermore, the 
model variants agreed that when biomarker prevalence was measured one or two years after scaling 
down control (excluding simulations in which a new VL case had already been detected before that 
time), sensitivity decreased strongly and specificity increased slightly. 
 
The PPV and NPV of thresholds for biomarker prevalence, as predicted by model E1, depended on 
both the biomarker as well as the time of measurement (Figure 3). In general, NPVs (i.e. the 
probability of no more VL cases if the biomarker prevalence was under the threshold) were higher 
for DAT (up to 99%) than for antigenaemia prevalence (up to 95%), as the latter were limited by the 






/cid/advance-article/doi/10.1093/cid/ciab210/6255961 by guest on 29 April 2021
 
 7 
prevalence, a threshold value of 6 positive individuals in a sample of 500 corresponded to a ≥95% 
probability that no further VL cases could occur, if DAT prevalence was measured at the moment of 
scale-down. For antigenaemia, this NPV of 95% could only just be achieved by allowing at most 1 
positive individual. The corresponding PPVs (i.e. the probability of recurring VL cases if biomarker 
prevalence is above or equal to the threshold) were ≥94% for both biomarkers. For both biomarkers, 
when prevalence was measured one or two years after scale-down, the PPV decreased and the NPV 
increased and flattened as a function of threshold value (i.e., if no new VL case had been detected by 
then, the a priori probability of recurrence had already strongly declined). Alternatively, when 
assuming that asymptomatic infections do not contribute to transmission (model E0), in general, 
NPVs were lower for DAT (80% to 90% for a threshold of 1 case) and particularly lower for 
antigenaemia (60% to 70% for a threshold of 1 case), although PPVs were still high (≥90%) (Figure 
S7). In contrast to model E1, in model E0, measuring biomarker prevalence one or two years after 
scaling down only marginally affected the PPV, yet still increased the NPV. Last, PPVs were robust to 
variation in pre-control endemicity both model E1 and E0 (Figures S8 and S9), provided that the 
biomarker and associated threshold prevalence are chosen aiming at a PPV and NPV ≥90%. Overall, 
NPVs were slightly higher for settings with high pre-control endemicity, reflecting that achieving a 
prevalence under the threshold despite more intense transmission conditions was highly indicative 
of successful control. 
 
Discussion 
We show that occurrence of new VL cases (reported or unreported) after achieving three years of 
zero reported VL cases and scaling down control efforts is highly correlated with the seroprevalence 
(based on DAT) and antigenaemia prevalence. Biomarker prevalence in adults (ages ≥15) provides 
the most predictive information on prospects of resurgence, and DAT prevalence appears to be a 
more informative predictor than antigenaemia prevalence. Thresholds for biomarker prevalence to 
predict occurrence of new VL cases with high certainty were robust to variation in pre-control 
endemicity, allowing thresholds to be applied without exact knowledge of transmission conditions. 
 
For an area covering a population of 10,000 people, having no DAT-positive individuals in a sample 
of 500 (i.e. a threshold of <1 case) at the moment of scale-down is a conservative approach to 
predicting whether or not new VL cases will occur. However, the predictive power of such a criterion 
does depend on whether or not asymptomatic individuals do (NPV ≥99%, PPV ≥79%) or do not 
contribute to transmission (NPV ≥80%, PPV ≥92%). In general, the predictive value could be further 
boosted by sampling more individuals (and adapting the threshold criterion accordingly) or by 
performing repeated surveys over time (e.g. annually). Of course, as this is a modelling study and 
given that no monitoring programme exists as suggested here, predictions should be validated based 
on field data, ideally longitudinal data of biomarker prevalence from areas that have implemented 
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A major strength of this study is that the calculated threshold values for the number of biomarker-
positive cases in a sample of 500 individuals can be readily used for interpretation of field data 
(based on the same sample size) without the need for calculating confidence bounds around 
prevalence estimates. This is possible because stochastic as well as statistical uncertainty are both 
captured in our calculations: stochastic uncertainty via many repeated simulations of the population 
dynamics over time, and statistical uncertainty via 100 repeated survey simulations within each 
transmission simulation. In addition, the methodology employed in this paper can be easily adapted 
to other population sizes and survey sample sizes. However, for much larger population sizes, model 
predictions should ideally be based on a metapopulation model that accounts for the fact that 
individuals live in subpopulations and do not mix homogeneously. Such a model would also address 
the most important limitation of this study that we assume a closed population without the 
possibility of introduction of infection from outside. Recrudescence of VL transmission through 
introduction via human mobility is a real risk, unless the strategy is successfully rolled-out at a very 
large scale. As such, the threshold for biomarker prevalence proposed here should be interpreted as 
an indicator of recurrence of VL transmission through local transmission. The metapopulation model 
that is needed to relax this assumption is current being developed. 
 
Our finding that thresholds for biomarker prevalence were quite robust to variation in pre-control 
endemicity is extremely convenient for policy development and implementation of monitoring in 
field settings. This robustness is in stark contrast with, for example, thresholds for Ov16-
seroprevalence to evaluate progress towards elimination of onchocerciasis, for which threshold 
values for a particular target predictive value strongly change with pre-control endemicity [17]. This 
is not the case for VL because of the precondition of three consecutive years of zero cases before 
scaling down control efforts. This ensures that if the target is met despite a high transmission 
potential, it is indicative of having interrupted transmission with high probability. Of course, this is 
conditional on meeting the target through high detection effort rather than low detection effort 
(causing fewer cases to be reported), for which we previously showed that it can lead to a 
“confirmatory” drop in case rates while true case numbers are rising [18]. Then again, if the 
monitoring strategy developed in this study would be applied to a situation where the target was 
met due to poor case detection, we expect that this would most likely be immediately reflected by a 
high biomarker prevalence. 
 
According to our findings, measuring biomarker prevalence at one or two years after scaling down 
control efforts (as long as no new VL cases have been detected in the meanwhile) increases the 
predictive power for absence of new VL cases (i.e. NPV), which was already very high when 
biomarker (especially DAT) prevalence was assessed at the moment of scale-down. This finding was 
mostly driven by the fact that if VL transmission resurged, it did so mostly within one year after 
scale-down; in other words, if no new VL cases were reported in the first year after scale-down, the 
probability of resurgence was very low to begin with, which drove up the NPV (and lowered the 
PPV). It is therefore important to note that the benefit of this higher NPV comes at the cost of 
delayed information, giving the infection more opportunity to be transmitted further throughout the 
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one year of scaling down, we recommend that a biomarker survey is performed at the moment of 
scale-down or slightly before. However, if the biomarker survey is performed much earlier than the 
3-year benchmark (say, one year before), threshold values for the number of positive cases would 
have to be adapted and might even depend more on pre-control endemicity. 
  
It is important to note that for the sake of illustrating the potential predictive value of biomarkers, in 
our simulations, we assumed that diagnostic tests for antibodies or antigens are 100% sensitive and 
specific at the individual level. However, in reality, false positive and false negative results should 
certainly be expected to occur, adding noise to observations and lowering the PPV and NPV of 
biomarker prevalence for recurrence of VL cases, compared to what we estimate here. Also, it 
should be noted that our model predictions for DAT prevalence are quantified based on the 
diagnostic techniques and titre thresholds used to calibrate our model to data from the KalaNet 
study [14,15]. For a more sensitive monitoring strategy (i.e., a higher chance of correctly identifying 
settings where new VL cases will occur), it might be advantageous to use a lower titre threshold for 
DAT positivity, although this would come at a cost of lower specificity (i.e., a higher risk of continuing 
control efforts longer than strictly necessary). An added benefit would be that the use of a lower 
titre threshold would result in higher prevalences overall, which would allow for a higher threshold 
of DAT prevalence in the survey sample and thus requiring a smaller sample size to conclude that the 
prevalence is statistically significant under the threshold. It is possible to capture this in our model 
but requires further model development and calibration using more detailed data on actual DAT 
titres. Data from the follow-up KalaNet study [19] will be particularly valuable here, as it would also 
allow us to further validate model predictions over time. Antigenaemia on the other hand was not 
found to be as good a predictive marker as DAT. This is presumably because individuals have a high 
detectable antigen load for a short period of time, especially when compared to the duration of 
detectable antibodies, and therefore the cycle of surveillance may not capture positive cases, 
especially with low numbers of participants surveyed. Antigen tests could instead be used to confirm 
findings of these population surveys, as a highly specific test.  
 
Our findings highlight the need for further operational research into effective monitoring to ensure 
sustained control of VL in the Indian subcontinent. First of off all, given our finding that population-
based surveys can be an extremely valuable monitoring tool when scaling down control, the 
question arises what geographical units such surveys should cover and how surveys should be 
implemented. For instance, how many communities and how many individuals should be selected 
per community? This would depend on the expected level of geographical clustering of VL 
transmission after prolonged control, which needs to be informed by field studies like the recent 
KalaNet follow-up study [19]. Second, how feasible is it to sample, say, 500 individuals per 10,000 
population? Sampling 5% of the population may be practically too demanding or too expensive, 
especially when surveys have to rely on lab facilities. Therefore, there is an urgent need for rapid 
point-of-care diagnostic tools to assess seroprevalence or antigenaemia in the general population. 
Of course, to define useful threshold values for biomarker prevalence measured by such tools, their 
sensitivity and specificity need to be carefully quantified. Third, there is a need to define more 
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cases have been detected yet. These actions may depend on the encountered prevalence of 
biomarker positivity: if biomarker positivity is highly clustered, more in-depth follow-up surveys of 
the locations with high biomarker prevalence may be an adequate first step; if biomarker positivity is 
more homogeneously distributed over a larger area, more immediate action in terms of reinstating 
IRS and/or ACD across the entire geographical area may be more appropriate. 
 
We conclude that the risk of recrudescence of VL after scaling down control efforts can be 
monitored and mitigated by means of population-based surveys. We recommend that such surveys 
are based on biomarkers of current and recent infection, such as antibodies, as prevalences for such 
biomarkers are higher than antigen prevalences and thus provide more statistical information. Our 
findings highlight that rapid point-of-care diagnostic tools to assess (preferably) seroprevalence or 
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Figure 1. Model-predicted trends in age-specific DAT prevalence after scaling down control 
efforts against visceral leishmaniasis. Lines represent biomarker prevalence from a randomly 
selected subset of 500 simulations. Rows represent different age categories; columns depict 
simulations that resulted in occurrence (left) or absence of new VL cases (right), with the total number 
of simulations per outcome indicated at the top of each column (N). Predictions are based on the 
assumptions that both symptomatic and asymptomatic infections contribute to transmission (model 
E1) and that all individuals are tested. Similar predictions assuming asymptomatic infections do not 
contribute to transmission (model E0) can be found in Figure S4. 
 
Figure 2. Receiver-operator curve for predicting occurrence of new VL cases based on age-
specific prevalence of DAT or antigenaemia measured at and up to two years after scaling 
down control efforts. Columns depict receiver-operator curves (ROC) based on biomarkers 
measured on three different time points; rows depict different biomarkers. Symbols indicate 
thresholds for the number (N) of biomarker-positive cases at or above which the recurrence of at least 
one VL case was predicted. Predictions are based on the assumptions that both symptomatic and 
asymptomatic infections contribute to transmission (model E1) and that 500 individuals are tested for 
biomarker positivity. Similar predictions assuming asymptomatic infections do not contribute to 
transmission (model E0) can be found in Figure S6. 
 
Figure 3. Positive (PPV) and negative predictive value (NPV) of DAT and antigenaemia 
prevalence in adults (age 15+) measured up to two years after scaling down control efforts, 
given a choice of threshold value. Columns depict curves based on biomarkers measured on three 
different time points; rows depict different biomarkers. Note that the predictive values based on 
biomarker prevalences measured one or two years after scale-down (middle and right panels) are 
conditional on no new VL cases having been detected since scale-down. Predictions are based on 
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(model E1) and that 500 individuals are tested for biomarker positivity. Similar predictions assuming 
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